Noclaud (Cilostazol)

Cilostazol, the active ingredient in Noclaud, is a phosphodiesterase 3 inhibitor presented as an oral tablet for oral use. It is prescribed to improve walking distance in adults with intermittent claudication secondary to peripheral arterial disease. The medication is formulated for systemic absorption and is indicated for patients who experience leg pain during exertion due to reduced arterial blood flow.

GNH USA supplies Noclaud as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cilostazol acts on the peripheral arterial circulation to relieve symptoms of reduced blood flow. - Intermittent claudication: improves walking distance and reduces leg pain during exercise. - Peripheral arterial disease: alleviates ischemic symptoms and enhances limb perfusion. - Symptomatic leg ischemia: increases blood flow to affected muscles, helping patients perform daily activities.

Cilostazol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: occasional loose stools. - Dizziness: transient light‑headedness. - Nausea: occasional upset stomach. - Palpitations: awareness of heartbeat. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Myocardial infarction: rare cardiac events. - Hepatic dysfunction: elevated liver enzymes. - Rhabdomyolysis: muscle breakdown with dark urine. - Anaphylaxis: life‑threatening allergic reaction.

Before initiating therapy with Noclaud, several precautionary measures should be considered. - Cardiovascular assessment: evaluate for heart failure or uncontrolled hypertension before use. - Bleeding risk: monitor for signs of abnormal bleeding, especially if combined with anticoagulants. - Liver function: assess hepatic enzymes and avoid in severe hepatic impairment. - Platelet count: check baseline and periodic monitoring for thrombocytopenia. - Pregnancy and lactation: avoid unless benefit outweighs risk, as safety data are limited. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Cilostazol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Macrolide antibiotics (e.g., erythromycin): elevated cilostazol plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): potential toxicity.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): additive inhibition of platelet function. - Diuretics: may enhance hypotensive effect. - Beta‑blockers: possible alteration of heart‑rate response.